Lung function and side effects of Aspirin desensitization: a real world study.

IF 1.8 Q3 RESPIRATORY SYSTEM European Clinical Respiratory Journal Pub Date : 2021-01-11 DOI:10.1080/20018525.2020.1869408
Turpeinen Heikki, Laulajainen-Hongisto Anu, Lyly Annina, Numminen Jura, Penttilä Elina, Johanna Sahlman, Toppila-Salmi Sanna, Kauppi Paula
{"title":"Lung function and side effects of Aspirin desensitization: a real world study.","authors":"Turpeinen Heikki, Laulajainen-Hongisto Anu, Lyly Annina, Numminen Jura, Penttilä Elina, Johanna Sahlman, Toppila-Salmi Sanna, Kauppi Paula","doi":"10.1080/20018525.2020.1869408","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction</b>: NSAID-exacerbated respiratory disease (N-ERD) is mainly treated with topical and oral corticosteroids, as well as acetylsalicylic acid (ASA) treatment after desensitization (ATAD). During desensitization and ATAD, it is common to experience an exacerbation of respiratory symptoms and other side effects, which may lead to cessation of treatment. <b>Objectives</b>: The aim of this retrospective follow-up study was to evaluate the effect of ATAD on lung functions and respiratory symptoms, and to clarify the occurrence of adverse events. <b>Method</b>s: We analysed the patient data of 67 patients treated with ASA desensitization between 2006 and 2016 in three hospitals, concerning adverse events, respiratory symptoms, lung function tests, and reasons for discontinuation. <b>Results</b>: 26 patients discontinued AD or ATAD. The most common reasons for discontinuation were lack of response (9%) and side effects (18%). ATAD did not affect lung function values in the follow-up of up to 5 years. Upper respiratory symptoms improved in 31 (52%) and lower respiratory symptoms (LRS) in 7 (10%) cases. Side effects occurred in 42 (63%) cases, the most common being dyspepsia and lower respiratory symptoms. <b>Conclusion</b>: Our study suggests that ATAD has little effect on lower airway functions. Side effects were common, and discontinuation rates high.</p>","PeriodicalId":11872,"journal":{"name":"European Clinical Respiratory Journal","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2021-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/20018525.2020.1869408","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Clinical Respiratory Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20018525.2020.1869408","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 4

Abstract

Introduction: NSAID-exacerbated respiratory disease (N-ERD) is mainly treated with topical and oral corticosteroids, as well as acetylsalicylic acid (ASA) treatment after desensitization (ATAD). During desensitization and ATAD, it is common to experience an exacerbation of respiratory symptoms and other side effects, which may lead to cessation of treatment. Objectives: The aim of this retrospective follow-up study was to evaluate the effect of ATAD on lung functions and respiratory symptoms, and to clarify the occurrence of adverse events. Methods: We analysed the patient data of 67 patients treated with ASA desensitization between 2006 and 2016 in three hospitals, concerning adverse events, respiratory symptoms, lung function tests, and reasons for discontinuation. Results: 26 patients discontinued AD or ATAD. The most common reasons for discontinuation were lack of response (9%) and side effects (18%). ATAD did not affect lung function values in the follow-up of up to 5 years. Upper respiratory symptoms improved in 31 (52%) and lower respiratory symptoms (LRS) in 7 (10%) cases. Side effects occurred in 42 (63%) cases, the most common being dyspepsia and lower respiratory symptoms. Conclusion: Our study suggests that ATAD has little effect on lower airway functions. Side effects were common, and discontinuation rates high.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
阿司匹林脱敏的肺功能和副作用:一项真实世界的研究。
nsaid加重的呼吸系统疾病(N-ERD)主要通过外用和口服皮质类固醇以及脱敏(ATAD)后的乙酰水杨酸(ASA)治疗来治疗。在脱敏和ATAD期间,通常会出现呼吸系统症状加重和其他副作用,这可能导致停止治疗。目的:本回顾性随访研究的目的是评估ATAD对肺功能和呼吸系统症状的影响,并澄清不良事件的发生。方法:我们分析了2006年至2016年在三家医院接受ASA脱敏治疗的67例患者的患者资料,包括不良事件、呼吸症状、肺功能检查和停药原因。结果:26例患者停用AD或ATAD。最常见的停药原因是缺乏反应(9%)和副作用(18%)。在长达5年的随访中,ATAD未影响肺功能值。31例(52%)上呼吸道症状改善,7例(10%)下呼吸道症状改善。42例(63%)发生副作用,最常见的是消化不良和下呼吸道症状。结论:本研究提示ATAD对下气道功能影响不大。副作用很常见,停药率很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.80
自引率
0.00%
发文量
15
审稿时长
16 weeks
期刊最新文献
Factors behind favorable long-term lung cancer survival in Norway compared to Denmark: a retrospective cohort study. Socioeconomic status and emergency department visits in adults with a history of severe childhood asthma: a register-based study. Comorbid allergy and rhinitis and patient-related outcomes in asthma and COPD: a cross-sectional study. Lung function measurements in the Greenlandic Inuit population: results from the Greenlandic health survey 2017-2019. Asthma severity: the patient's point of view.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1